| __timestamp | Dynavax Technologies Corporation | Opthea Limited |
|---|---|---|
| Wednesday, January 1, 2014 | 17763000 | 2652041 |
| Thursday, January 1, 2015 | 22180000 | 2361587 |
| Friday, January 1, 2016 | 37257000 | 4472869 |
| Sunday, January 1, 2017 | 27367000 | 5030957 |
| Monday, January 1, 2018 | 64770000 | 4988941 |
| Tuesday, January 1, 2019 | 74986000 | 5196412 |
| Wednesday, January 1, 2020 | 79256000 | 6652774 |
| Friday, January 1, 2021 | 100156000 | 18418247 |
| Saturday, January 1, 2022 | 131408000 | 24827066 |
| Sunday, January 1, 2023 | 152946000 | 41896408 |
| Monday, January 1, 2024 | 15488619 |
Unleashing the power of data
In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for financial health. Opthea Limited and Dynavax Technologies Corporation, two prominent players, showcase contrasting strategies over the past decade. From 2014 to 2023, Dynavax's SG&A expenses surged by over 760%, peaking in 2023. This reflects their aggressive expansion and investment in administrative capabilities. In contrast, Opthea's expenses grew by approximately 1,480%, indicating a more rapid scale-up, especially noticeable in 2023 when their costs reached 41% of Dynavax's. Despite missing data for 2024, Opthea's trend suggests a strategic pivot towards cost optimization. This analysis highlights the importance of balancing growth with cost efficiency, a lesson for emerging biotech firms aiming for sustainable success.
Who Optimizes SG&A Costs Better? AstraZeneca PLC or Dynavax Technologies Corporation
Comparing SG&A Expenses: Sanofi vs Opthea Limited Trends and Insights
SG&A Efficiency Analysis: Comparing Neurocrine Biosciences, Inc. and Dynavax Technologies Corporation
SG&A Efficiency Analysis: Comparing Summit Therapeutics Inc. and Dynavax Technologies Corporation
Cost Management Insights: SG&A Expenses for Exelixis, Inc. and Opthea Limited
Operational Costs Compared: SG&A Analysis of Grifols, S.A. and Opthea Limited
Ionis Pharmaceuticals, Inc. vs Opthea Limited: SG&A Expense Trends
SG&A Efficiency Analysis: Comparing Opthea Limited and ADMA Biologics, Inc.
Operational Costs Compared: SG&A Analysis of Opthea Limited and CRISPR Therapeutics AG
Who Optimizes SG&A Costs Better? Opthea Limited or ImmunityBio, Inc.
Ligand Pharmaceuticals Incorporated vs Dynavax Technologies Corporation: SG&A Expense Trends
Who Optimizes SG&A Costs Better? Dynavax Technologies Corporation or BioCryst Pharmaceuticals, Inc.